AR084102A1 - Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos - Google Patents
Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidosInfo
- Publication number
- AR084102A1 AR084102A1 ARP110104773A ARP110104773A AR084102A1 AR 084102 A1 AR084102 A1 AR 084102A1 AR P110104773 A ARP110104773 A AR P110104773A AR P110104773 A ARP110104773 A AR P110104773A AR 084102 A1 AR084102 A1 AR 084102A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- compressed
- dimethyl
- trioxo
- iodo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424967P | 2010-12-20 | 2010-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084102A1 true AR084102A1 (es) | 2013-04-24 |
Family
ID=46314827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104773A AR084102A1 (es) | 2010-12-20 | 2011-12-19 | Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos |
| ARP210101433A AR122185A2 (es) | 2010-12-20 | 2021-05-27 | Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101433A AR122185A2 (es) | 2010-12-20 | 2021-05-27 | Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos |
Country Status (38)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| AU2013352369B2 (en) * | 2012-11-30 | 2016-07-28 | Novartis Ag. | Novel pharmaceutical composition |
| WO2015019125A1 (en) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Molecular targets for the treatment of wounds, in particular chronic wounds |
| CN103819471A (zh) * | 2013-11-25 | 2014-05-28 | 镇江圣安医药有限公司 | 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用 |
| CN104918937B (zh) * | 2013-12-06 | 2016-09-14 | 杭州普晒医药科技有限公司 | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 |
| EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| US20170020880A1 (en) * | 2015-07-22 | 2017-01-26 | Hetero Research Foundation | Pharmaceutical compositions of trametinib |
| TWI777658B (zh) | 2016-08-10 | 2022-09-11 | 瑞士商赫孚孟拉羅股份公司 | 包含Akt蛋白質激酶抑制劑之醫藥組合物 |
| RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| JP2019535696A (ja) * | 2016-11-25 | 2019-12-12 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピリドン誘導体の医薬組成物およびその製造方法 |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| CN114340670B (zh) | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| EP4725489A2 (en) | 2019-08-02 | 2026-04-15 | OneHealthCompany, Inc. | Treatment of canine cancers |
| RU2749719C1 (ru) * | 2020-10-08 | 2021-06-16 | Нестерук Владимир Викторович | Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| WO2024171019A1 (en) * | 2023-02-13 | 2024-08-22 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of trametinib and process of preparation thereof |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| AU2005252110B2 (en) * | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| US7955622B2 (en) * | 2006-10-13 | 2011-06-07 | Actavis Group Ptc Hf | Controlled-release galantamine formulations |
| CA2668724A1 (en) * | 2006-11-09 | 2008-05-22 | Gilead Colorado, Inc. | Darusentan oral dosage form |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| UA99731C2 (ru) * | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение |
| BRPI0817946A2 (pt) * | 2007-09-25 | 2015-05-05 | Teva Pharma | Composições de imatinibe estável |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2392576B1 (en) * | 2008-07-08 | 2016-02-17 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| CN102762098B (zh) | 2009-09-23 | 2015-10-14 | 葛兰素史密斯克莱有限责任公司 | 组合 |
| AU2010298277B2 (en) | 2009-09-23 | 2014-07-03 | Novartis Ag | Combination |
| MX2012003779A (es) * | 2009-09-28 | 2012-06-01 | Glaxosmithkline Llc | Combinacion. |
| US8703781B2 (en) * | 2009-10-16 | 2014-04-22 | Glaxosmithkline Llc | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
| MX2012005758A (es) | 2009-11-17 | 2012-06-19 | Glaxosmithkline Llc | Combinacion. |
| EP2608790A4 (en) | 2010-08-26 | 2014-04-02 | Glaxosmithkline Llc | PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US8977217B1 (en) | 2013-02-20 | 2015-03-10 | Triquint Semiconductor, Inc. | Switching device with negative bias circuit |
| CZ2015278A3 (cs) | 2015-04-24 | 2016-11-02 | Zentiva, K.S. | Krystalické formy trametinibu |
-
2011
- 2011-12-16 TW TW100146692A patent/TWI505828B/zh active
- 2011-12-18 JO JOP/2011/0385A patent/JO3594B1/ar active
- 2011-12-19 AR ARP110104773A patent/AR084102A1/es not_active Application Discontinuation
- 2011-12-19 UY UY0001033818A patent/UY33818A/es active IP Right Grant
- 2011-12-20 DK DK22209107.6T patent/DK4159205T3/da active
- 2011-12-20 US US13/991,705 patent/US20130266649A1/en not_active Abandoned
- 2011-12-20 WO PCT/US2011/066021 patent/WO2012088033A2/en not_active Ceased
- 2011-12-20 PT PT118499748T patent/PT2654736T/pt unknown
- 2011-12-20 ES ES22209107T patent/ES2985024T3/es active Active
- 2011-12-20 MY MYPI2013701038A patent/MY170501A/en unknown
- 2011-12-20 PL PL22209107.6T patent/PL4159205T3/pl unknown
- 2011-12-20 LT LTEP22209107.6T patent/LT4159205T/lt unknown
- 2011-12-20 EP EP11849974.8A patent/EP2654736B1/en not_active Revoked
- 2011-12-20 BR BR112013015602-3A patent/BR112013015602B1/pt active IP Right Grant
- 2011-12-20 MX MX2013007073A patent/MX2013007073A/es active IP Right Grant
- 2011-12-20 RS RS20240519A patent/RS65497B1/sr unknown
- 2011-12-20 ES ES22209104T patent/ES2982775T3/es active Active
- 2011-12-20 EP EP22209104.3A patent/EP4159204B1/en active Active
- 2011-12-20 HU HUE11849974A patent/HUE050788T2/hu unknown
- 2011-12-20 US US13/330,949 patent/US8580304B2/en active Active
- 2011-12-20 EP EP20179788.3A patent/EP3808343A1/en active Pending
- 2011-12-20 DK DK11849974.8T patent/DK2654736T3/da active
- 2011-12-20 HR HRP20201409TT patent/HRP20201409T1/hr unknown
- 2011-12-20 ES ES11849974T patent/ES2820536T3/es active Active
- 2011-12-20 UA UAA201309128A patent/UA113158C2/uk unknown
- 2011-12-20 HU HUE22209107A patent/HUE066526T2/hu unknown
- 2011-12-20 CA CA2822701A patent/CA2822701C/en active Active
- 2011-12-20 NZ NZ612157A patent/NZ612157A/en unknown
- 2011-12-20 SI SI201131918T patent/SI2654736T1/sl unknown
- 2011-12-20 LT LTEP11849974.8T patent/LT2654736T/lt unknown
- 2011-12-20 DK DK22209104.3T patent/DK4159204T3/da active
- 2011-12-20 PL PL22209104.3T patent/PL4159204T3/pl unknown
- 2011-12-20 PE PE2013001442A patent/PE20140040A1/es active IP Right Grant
- 2011-12-20 RS RS20240518A patent/RS65496B1/sr unknown
- 2011-12-20 FI FIEP22209104.3T patent/FI4159204T3/fi active
- 2011-12-20 EA EA201390913A patent/EA025198B1/ru not_active IP Right Cessation
- 2011-12-20 LT LTEP22209104.3T patent/LT4159204T/lt unknown
- 2011-12-20 MA MA36106A patent/MA34883B1/fr unknown
- 2011-12-20 KR KR1020137019029A patent/KR101911109B1/ko active Active
- 2011-12-20 SI SI201132108T patent/SI4159205T1/sl unknown
- 2011-12-20 PH PH1/2013/501209A patent/PH12013501209A1/en unknown
- 2011-12-20 EP EP22209107.6A patent/EP4159205B1/en active Active
- 2011-12-20 AU AU2011349422A patent/AU2011349422B2/en active Active
- 2011-12-20 HR HRP20240564TT patent/HRP20240564T1/hr unknown
- 2011-12-20 HR HRP20240563TT patent/HRP20240563T1/hr unknown
- 2011-12-20 FI FIEP22209107.6T patent/FI4159205T3/fi active
- 2011-12-20 PT PT222091076T patent/PT4159205T/pt unknown
- 2011-12-20 PT PT222091043T patent/PT4159204T/pt unknown
- 2011-12-20 SG SG2013044037A patent/SG191054A1/en unknown
- 2011-12-20 PL PL11849974T patent/PL2654736T3/pl unknown
- 2011-12-20 SI SI201132109T patent/SI4159204T1/sl unknown
- 2011-12-20 JP JP2013546310A patent/JP6126014B2/ja active Active
- 2011-12-20 CN CN201180066851.0A patent/CN103998041B/zh active Active
- 2011-12-20 HU HUE22209104A patent/HUE066525T2/hu unknown
-
2013
- 2013-06-07 ZA ZA2013/04189A patent/ZA201304189B/en unknown
- 2013-06-10 IL IL226855A patent/IL226855A/en active IP Right Grant
- 2013-06-18 CL CL2013001779A patent/CL2013001779A1/es unknown
- 2013-06-18 DO DO2013000138A patent/DOP2013000138A/es unknown
- 2013-07-19 CR CR20130352A patent/CR20130352A/es unknown
- 2013-10-02 US US14/044,139 patent/US9271941B2/en active Active
- 2013-12-11 US US14/103,092 patent/US9399021B2/en active Active
- 2013-12-11 US US14/103,193 patent/US9155706B2/en active Active
-
2017
- 2017-01-19 JP JP2017007796A patent/JP2017137299A/ja not_active Withdrawn
-
2020
- 2020-09-24 CY CY20201100905T patent/CY1123376T1/el unknown
-
2021
- 2021-05-27 AR ARP210101433A patent/AR122185A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084102A1 (es) | Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| BR112015004244A2 (pt) | composição médica oralmente administrada | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| AR065096A1 (es) | Preparacion solida | |
| AR121359A2 (es) | Un comprimido veterinario sólido que se comprime directamente a partir del polvo que no se sometió a una etapa de granulación, que comprende meloxicam o una de sus sales farmacéuticamente aceptables y excipientes | |
| ES2574836T3 (es) | Formulación de liberación prolongada de nevirapina | |
| BRPI0709847B8 (pt) | composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio | |
| CR20110704A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| CO6640305A2 (es) | Elaboración de gránulos sin activos y tabletas que comprenden los mismos | |
| CN103585126A (zh) | 一种托法替尼组合物及制备方法 | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| HRP20180219T1 (hr) | Sredstvo za uporabu u slučaju netolerancije na fruktozu | |
| BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
| AR097512A1 (es) | Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir | |
| RU2017126111A (ru) | Сложные капсулы, содержащие ралоксифен и витамин D и его производные | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| PE20221446A1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| EA201991359A1 (ru) | Фармацевтические лекарственные формы | |
| PE20150935A1 (es) | Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio | |
| UA91281U (uk) | Спосіб одержання фармацевтичного препарату, що має виражену антигестагенну дію |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |